---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-006317"
form_type: "8-K"
ticker: "PROF"
cik: "0001628808"
company_name: "Profound Medical Corp."
filed_at: "2025-10-07T23:59:59+00:00"
generated_at: "2026-05-17T04:26:45.325481+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Profound Medical reports preliminary Q3 revenue $5.2-5.3M, up 84-87% YoY

## Summary
- Preliminary unaudited Q3 2025 revenue of $5.2-5.3M vs $2.8M in Q3 2024, growth 84-87%.
- Gross margin expected ~72% compared to 64% in prior-year period.
- TULSA-PRO installed base grew to 67 from 60; full-year target of at least 75 systems.
- Full Q3 2025 results and conference call scheduled for November 13, 2025.

## SEC filing metadata
- accession: 0001171843-25-006317
- form_type: 8-K
- ticker: PROF
- cik: 0001628808
- company_name: Profound Medical Corp.
- filed_at: 2025-10-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628808/000117184325006317/0001171843-25-006317-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628808/000117184325006317/f8k_100725.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-006317
- JSON: https://secwatch.observer/filing/0001171843-25-006317.json
- Plain text: https://secwatch.observer/filing/0001171843-25-006317.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.